|
WO2021028439A1
|
|
Rna combinations and compositions with decreased immunostimulatory properties
|
|
WO2020254535A1
|
|
Rotavirus mrna vaccine
|
|
WO2020161342A1
|
|
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
WO2020128031A2
|
|
Rna for malaria vaccines
|
|
WO2020127959A1
|
|
Methods for rna analysis
|
|
WO2020002598A1
|
|
Bioreactor for rna in vitro transcription
|
|
WO2020002525A1
|
|
Novel lassa virus rna molecules and compositions for vaccination
|
|
SG11202008225PA
|
|
Novel rsv rna molecules and compositions for vaccination
|
|
WO2019193183A2
|
|
Novel yellow fever nucleic acid molecules for vaccination
|
|
CN111511928A
|
|
Linear double-stranded DNA coupled to a single support or tag and method for preparing the same
|
|
EP3723796A1
|
|
Flavivirus vaccine
|
|
WO2019092153A1
|
|
Rna sequence adaptation
|
|
AU2018351481A1
|
|
Novel artificial nucleic acid molecules
|
|
WO2019038332A1
|
|
Bunyavirales vaccine
|
|
CA3066932A1
|
|
Novel nucleic acid molecules
|
|
WO2018211038A1
|
|
Method for determining at least one quality parameter of an rna sample
|
|
CA3050616A1
|
|
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
CN110392577A
|
|
For combining the RNA vaccine and immunologic test point inhibitor of anti-cancer therapies
|
|
US2019351048A1
|
|
Mers coronavirus vaccine
|
|
US2019351047A1
|
|
Henipavirus vaccine
|
